Enviar artigo por via de e-mail Controversial Points in the Assessment of the Quality of Generic Esomeprazole Formulations
- Autores: Serebrova S.Y.1,2, Prokof’ev A.B.1,2, Krasnykh L.M.1, Vasilenko G.F.1, Smolyarchuk E.A.2, Kareva E.N.2,3, Smirnov V.V.1,2, Zhuravleva M.V.1,2, Eremenko N.N.1,2, Lazareva N.B.2, Starodubtsev A.K.2, Kurguzova D.O.2, Barkov A.O.2, Abrosimov A.G.2, Koniev T.I.2, Sivkov A.S.2, Temirbulatov I.I.2
-
Afiliações:
- Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
- I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
- N. I. Pirogov Russian National Medical Research University, Ministry of Health of the Russian Federation
- Edição: Volume 53, Nº 1 (2019)
- Páginas: 1-5
- Seção: Molecular Biological Problems of Drug Design and Mechanism of Drug Action
- URL: https://journals.rcsi.science/0091-150X/article/view/245589
- DOI: https://doi.org/10.1007/s11094-019-01946-9
- ID: 245589
Citar
Acesso aberto
Acesso está concedido
Somente assinantes
Resumo
A comparative dissolution kinetics test was performed to model the actions of pathological duodenogastric reflux and therapeutic acid suppression on the stability of esomeprazole formulations from three different manufacturers. After exposure to solutions pH (1.2 ±0.05) or (4.0 ±0.05), formulations were transferred to medium pH (7.0 ±0.05), from which aliquots were collected at 0, 4, 10, 15, 20, 30, 45, and 60 min for estimation of esomeprazole concentrations. The duration of exposure of the medicinal formulation of esomeprazole to pathological duodenogastric refluxate was 4 min. In these test conditions, Generic-1 and Generic-2 were found not to be equivalent to the reference drug (RD); the medicinal formulation of the RD was probably influenced by pathological duodenogastric reflux in the stomach, while Generic-2 was completely degraded in moderately acidic medium pH 4.0, which is evidence of the possible adverse influence of its main antisecretory pharmacodynamic effect of the intragastric stability of the medicinal formulation and the active substance.
Sobre autores
S. Serebrova
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
Autor responsável pela correspondência
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 PetrovskiiProspekt, Moscow, 127051; Building 2, 8 Trubetskaya Street, Moscow, 119991
A. Prokof’ev
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 PetrovskiiProspekt, Moscow, 127051; Building 2, 8 Trubetskaya Street, Moscow, 119991
L. Krasnykh
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 PetrovskiiProspekt, Moscow, 127051
G. Vasilenko
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 PetrovskiiProspekt, Moscow, 127051
E. Smolyarchuk
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 Trubetskaya Street, Moscow, 119991
E. Kareva
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University); N. I. Pirogov Russian National Medical Research University, Ministry of Health of the Russian Federation
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 Trubetskaya Street, Moscow, 119991; 1 Ostrovityanova Street, Moscow, 117997
V. Smirnov
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 PetrovskiiProspekt, Moscow, 127051; Building 2, 8 Trubetskaya Street, Moscow, 119991
M. Zhuravleva
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 PetrovskiiProspekt, Moscow, 127051; Building 2, 8 Trubetskaya Street, Moscow, 119991
N. Eremenko
Scientific Center for Expert Evaluation of Medicinal Products, Ministry of Health of the Russian Federation; I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 PetrovskiiProspekt, Moscow, 127051; Building 2, 8 Trubetskaya Street, Moscow, 119991
N. Lazareva
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 Trubetskaya Street, Moscow, 119991
A. Starodubtsev
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 Trubetskaya Street, Moscow, 119991
D. Kurguzova
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 Trubetskaya Street, Moscow, 119991
A. Barkov
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 Trubetskaya Street, Moscow, 119991
A. Abrosimov
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 Trubetskaya Street, Moscow, 119991
T. Koniev
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 Trubetskaya Street, Moscow, 119991
A. Sivkov
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 Trubetskaya Street, Moscow, 119991
I. Temirbulatov
I. M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation (Sechenov University)
Email: maryjane.gargar@springer.com
Rússia, Building 2, 8 Trubetskaya Street, Moscow, 119991
Arquivos suplementares
